A Phase II Multicenter Study to Assess the Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor
Latest Information Update: 07 Apr 2025
At a glance
- Drugs Pembrolizumab (Primary) ; Vactosertib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
Most Recent Events
- 02 Apr 2025 Status changed from not yet recruiting to discontinued.
- 01 Jul 2022 New trial record